Lilly Jaypirca CHMP Backs EU Approval for CLL Treatment
INDIANAPOLIS, June 26, 2026 Eli Lilly and Company announced that the European Medicines Agency’s Committee for Medicinal Products for...
Jaypirca
Advertisement
Lilly’s Jaypirca Reduces Risk of Disease Progression or Death by 45% in CLL/SLL
INDIANAPOLIS, Indiana, June 14, 2026 Eli Lilly and Company announced compelling results from the pivotal Phase 3 BRUIN CLL-322...
Eli Lilly Reports Breakthrough Phase 3 Jaypirca Results
Indianapolis, Indiana | April 13, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3...
Jaypirca Gains Approval as First Non-Covalent BTK Inhibitor for CLL/SLL
INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...
Advertisement
